R&D Views & Analysis | pharmaphorum

Views & Analysis

R&D

Closed and Collaborative: Mergers, acquisitions, and partner...

Summer’s stretch having drawn out a longer return to our round-ups, as the days shorten and we firmly enter autumn, pharmaphorum takes a look back at the industry

/themes/custom/pharmaphorum_theme/library/img/article-label-image/ondemand.png

R&D

Beyond clinical: Boosting recruitment and retention with SDO...

The success of clinical trials hinges on a complex array of factors, many of which extend beyond traditional clinical care.

Patients

5 patient travel strategies to impact enrolment diversity in...

According to the latest CISCRP report, “having to travel to the study clinic” is patients’ top-cited participation burden

R&D

Supply chain resilience in pharma: Delivering consistency am...

In an interconnected economy, industries operating on an international scale are increasingly vulnerable to supply chain disruption.

R&D

Reducing drug shortages: The power of AI in pharma supply ch...

Drug shortages have long been a challenge in the pharmaceutical industry, causing significant disruptions to patient care and public health.

R&D

LSX World Congress – Day Two

On Day Two of 2024's LSX World Congress, we’ll hear about the biotech/biopharma IPO market, the 2024 US Presidential election, and about the future of digital health.